Status:
COMPLETED
Characterisation of Nasal Polyps in Patients With and Without Aspirin-exacerbated Respiratory Disease
Lead Sponsor:
Medical University of Vienna
Collaborating Sponsors:
AstraZeneca
Conditions:
Polyp Sinus
Eligibility:
All Genders
18-90 years
Brief Summary
Prevalence of aspirin-exacerbated respiratory disease (AERD) is 16% amongst patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). The mechanisms underlying the observed dysregulat...
Detailed Description
Chronic rhinosinusitis (CRS) with (w) and without (s) nasal polyps (NP) in its different shapes is currently affecting up to 16% of the total population of the United States and around 11% of the popu...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Male or Female
- Age: 18-90
- Willingness to participate in the study
- Suffering from CRSwNP (with or without prior history of surgery for nasal polyposis)
- Allergic or non-allergic: if no recent allergy test is available (max. two years old) the presence or absence of allergy will be determined by skin prick test and by ImmunoCAP for allergen-specific serum immunoglobulin E (IgE) levels in addition to assessment of patients's history by questionnaire.
- Suffering from AERD or not as confirmed by provocation testing
- Exclusion criteria:
- Children
- Pregnant women - the presence of a known pregnancy will be assessed during the visit by questionnaire
- A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study
Exclusion
Key Trial Info
Start Date :
February 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2019
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT03848156
Start Date
February 12 2019
End Date
November 30 2019
Last Update
January 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090